ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 838,61
0,02%
Dow Jones
44 156,73
0,30%
DAX
21 269,95
0,05%
Brent Oil
78,56
0,29%
Bitcoin
102 207,74
-1,38%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Tyra Biosciences Inc (TYRA)

  7. Tyra Biosciences Inc (TYRA) Actualités

TYRA

Tyra Biosciences (TYRA)

Tyra Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TYRA
DateHeureSourceTitreSymboleSociété
23/01/202500h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
22/01/202514h00PR Newswire (US)Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:TYRATyra Biosciences Inc
10/01/202514h00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)NASDAQ:TYRATyra Biosciences Inc
07/12/202403h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
13/11/202422h05PR Newswire (US)Tyra Biosciences to Present at Upcoming Investor ConferencesNASDAQ:TYRATyra Biosciences Inc
07/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
07/11/202422h05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
28/10/202412h00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)NASDAQ:TYRATyra Biosciences Inc
25/10/202400h21PR Newswire (US)Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)NASDAQ:TYRATyra Biosciences Inc
23/10/202422h05PR Newswire (US)Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETNASDAQ:TYRATyra Biosciences Inc
23/10/202402h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
23/10/202402h47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
11/10/202414h00PR Newswire (US)Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)NASDAQ:TYRATyra Biosciences Inc
11/09/202422h05PR Newswire (US)Tyra Biosciences to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:TYRATyra Biosciences Inc
10/09/202422h05PR Newswire (US)Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical OfficerNASDAQ:TYRATyra Biosciences Inc
07/08/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TYRATyra Biosciences Inc
07/08/202422h05PR Newswire (US)Tyra Biosciences Reports Second Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
02/07/202422h05PR Newswire (US)Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)NASDAQ:TYRATyra Biosciences Inc
09/05/202422h05PR Newswire (US)Tyra Biosciences Reports First Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
07/05/202422h34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TYRATyra Biosciences Inc
07/05/202422h05PR Newswire (US)Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of DirectorsNASDAQ:TYRATyra Biosciences Inc
19/03/202421h05PR Newswire (US)Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
13/02/202422h36Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:TYRATyra Biosciences Inc
07/02/202422h05PR Newswire (US)Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences ConferenceNASDAQ:TYRATyra Biosciences Inc
02/02/202414h00PR Newswire (US)Tyra Biosciences, Inc. Announces $200 Million Private Placement FinancingNASDAQ:TYRATyra Biosciences Inc
01/02/202423h30PR Newswire (US)Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of AchondroplasiaNASDAQ:TYRATyra Biosciences Inc
22/12/202315h00PR Newswire (US)Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300NASDAQ:TYRATyra Biosciences Inc
08/11/202322h05PR Newswire (US)Tyra Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:TYRATyra Biosciences Inc
07/11/202322h05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2023 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
21/09/202314h00PR Newswire (US)Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual MeetingsNASDAQ:TYRATyra Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:TYRA

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
EU
CAP
Capgemini
EU
AI
Air Liquide
EU
PX1
CAC 40
NYSE
JPM
JP Morgan Chase
EU
VIV
Vivendi
EU
DG
Vinci
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
NASDAQ
MSFT
Microsoft
EU
BN
Danone
EU
RNO
Renault
EU
ML
Michelin
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés